These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
551 related articles for article (PubMed ID: 34817311)
1. Management of chronic kidney disease in type 2 diabetes: screening, diagnosis and treatment goals, and recommendations. Shubrook JH; Neumiller JJ; Wright E Postgrad Med; 2022 May; 134(4):376-387. PubMed ID: 34817311 [TBL] [Abstract][Full Text] [Related]
2. Non-steroidal mineralocorticoid antagonists and hyperkalemia monitoring in chronic kidney disease patients associated with type II diabetes: a narrative review. Morales J; Palmer BF Postgrad Med; 2024 Mar; 136(2):111-119. PubMed ID: 38344772 [TBL] [Abstract][Full Text] [Related]
3. High unmet treatment needs in patients with chronic kidney disease and type 2 diabetes: real-world evidence from a US claims database. Fried L; Schmedt N; Folkerts K; Bowrin K; Raad H; Batech M; Kovesdy C Nephrol Dial Transplant; 2023 Feb; 38(3):630-643. PubMed ID: 35389468 [TBL] [Abstract][Full Text] [Related]
4. Chronic Kidney Disease and SGLT2 Inhibitors: A Review of the Evolving Treatment Landscape. Mende CW Adv Ther; 2022 Jan; 39(1):148-164. PubMed ID: 34846711 [TBL] [Abstract][Full Text] [Related]
5. Importance of Early Screening and Diagnosis of Chronic Kidney Disease in Patients with Type 2 Diabetes. Skolnik NS; Style AJ Diabetes Ther; 2021 Jun; 12(6):1613-1630. PubMed ID: 33914300 [TBL] [Abstract][Full Text] [Related]
6. Concordance With Screening and Treatment Guidelines for Chronic Kidney Disease in Type 2 Diabetes. Edmonston D; Lydon E; Mulder H; Chiswell K; Lampron Z; Marsolo K; Goss A; Ayoub I; Shah RC; Chang AR; Ford DE; Jones WS; Fonesca V; Machineni S; Fort D; Butler J; Hunt KJ; Pitlosh M; Rao A; Ahmad FS; Gordon HS; Hung AM; Hwang W; Bosworth HB; Pagidipati NJ JAMA Netw Open; 2024 Jun; 7(6):e2418808. PubMed ID: 38922613 [TBL] [Abstract][Full Text] [Related]
7. The dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial: baseline characteristics. Wheeler DC; Stefansson BV; Batiushin M; Bilchenko O; Cherney DZI; Chertow GM; Douthat W; Dwyer JP; Escudero E; Pecoits-Filho R; Furuland H; Górriz JL; Greene T; Haller H; Hou FF; Kang SW; Isidto R; Khullar D; Mark PB; McMurray JJV; Kashihara N; Nowicki M; Persson F; Correa-Rotter R; Rossing P; Toto RD; Umanath K; Van Bui P; Wittmann I; Lindberg M; Sjöström CD; Langkilde AM; Heerspink HJL Nephrol Dial Transplant; 2020 Oct; 35(10):1700-1711. PubMed ID: 32862232 [TBL] [Abstract][Full Text] [Related]
8. Barriers to early diagnosis of chronic kidney disease and use of sodium-glucose cotransporter-2 inhibitors for renal protection: A comprehensive review and call to action. Czupryniak L; Mosenzon O; Rychlík I; Clodi M; Ebrahimi F; Janez A; Kempler P; Małecki M; Moshkovich E; Prázný M; Sourij H; Tankova T; Timar B Diabetes Obes Metab; 2024 Oct; 26(10):4165-4177. PubMed ID: 39140231 [TBL] [Abstract][Full Text] [Related]
9. Early Identification and Management of Chronic Kidney Disease: A Narrative Review of the Crucial Role of Primary Care Practitioners. Kushner P; Khunti K; Cebrián A; Deed G Adv Ther; 2024 Oct; 41(10):3757-3770. PubMed ID: 39162984 [TBL] [Abstract][Full Text] [Related]
10. Prevalence of Chronic Kidney Disease in Type 2 Diabetes: The Canadian REgistry of Chronic Kidney Disease in Diabetes Outcomes (CREDO) Study. Chu L; Fuller M; Jervis K; Ciaccia A; Abitbol A Clin Ther; 2021 Sep; 43(9):1558-1573. PubMed ID: 34426012 [TBL] [Abstract][Full Text] [Related]
11. How Would You Manage This Patient With Type 2 Diabetes and Chronic Kidney Disease? Grand Rounds Discussion From Beth Israel Deaconess Medical Center. Smetana GW; Romeo GR; Rosas SE; Burns RB Ann Intern Med; 2024 Jun; 177(6):800-811. PubMed ID: 38857499 [TBL] [Abstract][Full Text] [Related]
12. Clinical implications and guidelines for CKD in type 2 diabetes. Zhang RM; Persson F; McGill JB; Rossing P Nephrol Dial Transplant; 2023 Feb; 38(3):542-550. PubMed ID: 36264310 [TBL] [Abstract][Full Text] [Related]
13. Diabetes management in chronic kidney disease: a consensus report by the American Diabetes Association (ADA) and Kidney Disease: Improving Global Outcomes (KDIGO). de Boer IH; Khunti K; Sadusky T; Tuttle KR; Neumiller JJ; Rhee CM; Rosas SE; Rossing P; Bakris G Kidney Int; 2022 Nov; 102(5):974-989. PubMed ID: 36202661 [TBL] [Abstract][Full Text] [Related]
14. Rationale and design of an investigator-initiated, multicenter, prospective open-label, randomized trial to evaluate the effect of ipragliflozin on endothelial dysfunction in type 2 diabetes and chronic kidney disease: the PROCEED trial. Tanaka A; Shimabukuro M; Okada Y; Sugimoto K; Kurozumi A; Torimoto K; Hirai H; Node K; Cardiovasc Diabetol; 2020 Jun; 19(1):85. PubMed ID: 32534578 [TBL] [Abstract][Full Text] [Related]
15. Management of type 2 diabetes in chronic kidney disease. Triozzi JL; Parker Gregg L; Virani SS; Navaneethan SD BMJ Open Diabetes Res Care; 2021 Jul; 9(1):. PubMed ID: 34312158 [TBL] [Abstract][Full Text] [Related]
16. Effect of Dapagliflozin on Cardiovascular Outcomes According to Baseline Kidney Function and Albuminuria Status in Patients With Type 2 Diabetes: A Prespecified Secondary Analysis of a Randomized Clinical Trial. Zelniker TA; Raz I; Mosenzon O; Dwyer JP; Heerspink HHJL; Cahn A; Goodrich EL; Im K; Bhatt DL; Leiter LA; McGuire DK; Wilding JPH; Gause-Nilsson I; Langkilde AM; Sabatine MS; Wiviott SD JAMA Cardiol; 2021 Jul; 6(7):801-810. PubMed ID: 33851953 [TBL] [Abstract][Full Text] [Related]
17. Diabetes Management in Chronic Kidney Disease: Synopsis of the KDIGO 2022 Clinical Practice Guideline Update. Navaneethan SD; Zoungas S; Caramori ML; Chan JCN; Heerspink HJL; Hurst C; Liew A; Michos ED; Olowu WA; Sadusky T; Tandon N; Tuttle KR; Wanner C; Wilkens KG; Craig JC; Tunnicliffe DJ; Tonelli M; Cheung M; Earley A; Rossing P; de Boer IH; Khunti K Ann Intern Med; 2023 Mar; 176(3):381-387. PubMed ID: 36623286 [TBL] [Abstract][Full Text] [Related]
18. A New Hope on the Horizon for Kidney and Cardiovascular Protection with SGLT2 Inhibitors, GLP-1 Receptor Agonists, and Mineralocorticoid Receptor Antagonists in Type 2 Diabetic and Chronic Kidney Disease Patients. Spasovski G; Rroji M; Hristov G; Bushljetikj O; Spahia N; Rambabova Bushletikj I Metab Syndr Relat Disord; 2024 Apr; 22(3):170-178. PubMed ID: 38386800 [TBL] [Abstract][Full Text] [Related]
19. Estimated health economic impact of conducting urine albumin-to-creatinine ratio testing alongside estimated glomerular filtration rate testing in the early stages of chronic kidney disease in patients with type 2 diabetes. Rossing P; Groehl F; Mernagh P; Folkerts K; Garreta-Rufas A; Harris J; Meredith K; Carter M; Åkerborg Ö; Wanner C; Hobbs FDR J Med Econ; 2023; 26(1):935-943. PubMed ID: 37439218 [TBL] [Abstract][Full Text] [Related]
20. Making an impact on kidney disease in people with type 2 diabetes: the importance of screening for albuminuria. McGill JB; Haller H; Roy-Chaudhury P; Cherrington A; Wada T; Wanner C; Ji L; Rossing P BMJ Open Diabetes Res Care; 2022 Jul; 10(4):. PubMed ID: 35790319 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]